Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 38,394

Document Document Title
WO/2019/177243A1
Disclosed are: a compound represented by chemical formula 1, an organic electronic element comprising a first electrode, a second electrode and an organic material layer between the first electrode and the second electrode; and an electr...  
WO/2019/174577A1
The present invention discloses phthalazine isoxazole alkoxy derivatives, a preparation method thereof, a pharmaceutical composition, and a use thereof. The present invention provides a compound represented by Formula I, cis-trans isomer...  
WO/2019/174607A1
The present invention relates to a dihydropyridophthalazinone derivative as represented by formula (I), and a preparation method therefor and an application thereof. the R1, R2, R3, m, n, ring A, and ring B in the formula are as defined ...  
WO/2019/174598A1
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2019/177971A1
Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the tre...  
WO/2019/174576A1
Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof. (I-1), (I-2)  
WO/2019/178368A1
The disclosure is directed to compounds of Formula I, which are inhibitors of protein methyltransferase 5 (PRMT5). Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also d...  
WO/2019/172200A1
Provided are: a compound which has a higher fluorescence quantum yield and higher light stability than conventional FLAPs; and a polymeric compound including said compound. The problem of the present invention can be solved by providing ...  
WO/2019/170729A1
The present application relates to an amine compound according to formula (I), (II) or (III) which is suitable for use in electronic devices.  
WO/2019/173551A1
The present disclosure relates to crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5 -yl)imidazo[l,2-a]pyrazine, which are useful as a stimulator of soluble guanylate cyclase (sGC). The present disclosure a...  
WO/2019/170691A1
The present application relates to an amine compound of formula (I) which is suitable for use in electronic devices.  
WO/2019/173790A1
The various examples presented herein are directed to compounds of the formula A-L1-Het1-L2-Cy1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyc...  
WO/2019/170543A1
The present invention covers heterocyclic compounds of general formula (I) in which T, U, Y, Z, R1 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceuti...  
WO/2019/173500A1
A compound that is a pyrazolo[4,3-d]pyrimidine, and optionally a salt or a hydrate thereof, is disclosed. A pharmaceutical composition comprising a compound that is a pyrazolo[4,3-d]pyrimidine, and optionally a salt or a hydrate of the c...  
WO/2019/173548A1
The invention relates to novel methods for preparing 3-substituted 1,2,4-triazole compounds as sGC stimulators and their synthetic precursors.  
WO/2019/172647A1
The present specification provides a compound of formula 1 and an organic light emitting device comprising same.  
WO/2019/173613A1
Disclosed are compounds, pharmaceutical compositions, and methods of treatment. The disclosed compounds are based on fused 1,4-diazepine and pyrrolidinedione scaffolds. The compounds may be utilized in pharmaceutical compositions and met...  
WO/2019/166950A1
The present disclosure refers to 10-(di(phenyl)methyl)-4- hydroxy-8,9,9a,10-tetrahydro-7H-pyrrolo[1';2':4,5]pyrazino[1 ,2- b]pyridazine-3,5-dione derivatives and related compounds of Formula (A) as inhibitors of the orthomyxovirus replic...  
WO/2019/165967A1
A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases.  
WO/2019/167068A1
The present invention discloses novel crystalline polymorphic forms of ribociclib succinate, methods of preparation, pharmaceutical compositions and methods of therapeutic treatment involving polymorphic forms thereof.  
WO/2019/167000A1
The invention provides new pyrazine derivatives of formula (I), or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical composit...  
WO/2019/168847A1
This application relates to compounds of Formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatme...  
WO/2019/169333A1
Described herein are compounds of Formula (I), modified polymers and implantable elements comprising compounds of Formula (II), as well as compositions and methods of use thereof. In particular, the compounds, modified polymers, implanta...  
WO/2019/070709A8
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.  
WO/2019/169249A1
Methods for treating a Human Immunodeficiency Virus (HIV) infection comprising administering to a subject in need of treatment thereof an effective amount of a small molecule nSMase2 inhibitor.  
WO/2019/167982A1
The present invention pertains to: a saturated ring-condensed dihydropyrimidinone or dihydrotriazinone compound having RORĪ³ antagonist activity or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing same;...  
WO/2019/169111A1
The present disclosure provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Rx-R8 are defined herein. Also provided are compositions comprising a compound described herein and a...  
WO/2019/166951A1
The invention provides compounds of Formula (I), as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds,...  
WO/2019/161748A1
Provided are organic semiconducting compounds containing a polycyclic unit, methods for their preparation and educts or intermediates used therein, compositions, polymer blends and formulations containing them, the use of the compounds, ...  
WO/2019/162524A1
The invention relates to chemical compounds that can be used in particular as structural mimetics of proline-rich peptides. The compounds of the invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein inter...  
WO/2019/163956A1
Provided are a salt of the compound represented by formula (I) and crystals thereof. The salt and crystals can be used as bulks drugs for pharmaceuticals.  
WO/2019/162964A1
The present disclosure discloses a composition comprising pranlukast or sorafenib. The present disclosure further discloses use of pranlukast or sorafenib for treating Mycobacterium infections. The present disclosure also discloses a met...  
WO/2019/164846A1
The present invention relates to N-(phenyl)-2-(phenyl)pyrimidine-4- carboxamide derivatives and related compounds of formula I as HPK1 (Hematopoietic progenitor kinase 1) inhibitors for treating cancer, such as e.g. breast cancer, colore...  
WO/2019/161494A1
It is provided a method of expanding dendritic (DC) cells and/or natural killer (NK) cells in vivo in a patient comprising the steps of producing a graft of stem and progenitor cells cultured with UM171 or analogues therefrom and expande...  
WO/2019/161803A1
The present invention provides a peptidylarginine deiminase PAD4 inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer and tautomer thereof, and a pharmaceutical composition, a pharmaceutical p...  
WO/2019/164341A1
The present specification relates to a spiro compound of chemical formula 1 and an organic light-emitting device comprising same.  
WO/2019/165204A1
The disclosure includes compounds of Formula (I) wherein Q, R1, R2, and m are defined herein. Also disclosed is a method for treating a neoplastic disease with these compounds.  
WO/2019/162332A1
The invention relates to an organic molecule, in particular for use in optoelectronic devices. According to the invention, the organic molecule has - a first chemical moiety with of a structure of Formula (I), and - one or two second che...  
WO/2019/164847A1
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...  
WO/2019/165073A1
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further ...  
WO/2019/165192A1
Indazole compounds of Formula (I) and their use in treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disord...  
WO/2019/165374A1
This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.  
WO/2019/161152A1
The disclosure includes compounds of Formula (I), wherein Q1, Q2, Q3, W, X, Y, Z1, m, n, Warhead, R1, R2, R3, R4, and R5, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammat...  
WO/2019/158655A1
New pyrimidine derivatives of formula (I), optionally with a detectable isotope, pharmaceutical composition and method of preparation thereof. New pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host...  
WO/2019/158107A1
Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a phar...  
WO/2019/158075A1
The present invention provides a benzodiazepine derivative hydrochloride represented by formula I or a crystal structure of an ethanolate thereof, wherein R is methyl or ethyl. The present invention further provides a method for preparin...  
WO/2019/158019A1
Disclosed in the present invention are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present invention are a pr...  
WO/2019/159097A1
The present invention relates to crystalline Form S and Form S2 of acalabrutinib, processes for their preparation, pharmaceutical composition comprising them, and their use for the treatment of adult patients with mantle cell lymphoma (M...  
WO/2019/157879A1
The present invention relates to a compound, a pharmaceutical composition containing the compound, a preparation method for the compound, and a use of the compound as a TRK inhibitor. The compound is the compound as shown in formula (I),...  
WO/2019/161320A1
The present disclosure provides methods of treating a cancer in a subject. The method includes a step of measuring a base level of a biomarker selected from a group consisting of hepatocyte growth factor, absolute neutrophil count, c-Met...  

Matches 1 - 50 out of 38,394